Short answer
LB PHARMACEUTICALS INC (LBRX) filed an 8-K current report with the SEC on March 10, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Robert A. Lenz appointed to Board Mar 6, 2026; Class I director term expiring 2026 annual meeting; joins Nominating and Corporate Governance Committee.
LB PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Robert A. Lenz appointed to Board Mar 6, 2026; Class I director term expiring 2026 annual meeting; joins Nominating and Corporate Governance Committee
- Lenz compensation: $45,000 total annual retainer ($40K board + $5K committee) plus initial 20,000-share option grant vesting over 3 years
- Gad Soffer promoted from Chief Business Officer to Chief Operating and Business Officer effective Mar 4, 2026
- Soffer salary raised to $505,000 with 40% target annual bonus (~$202,000 at target)
Item 7.01 · Regulation FD Disclosure
- Dr. Lenz appointed to Board of Directors, effective March 9, 2026
- Board composition change signals potential strategic or scientific advisory shift for LBRX
- Full details on Dr. Lenz's background and role scope available in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LB PHARMACEUTICALS INC 8-K filings
Get the next LBRX 8-K as it lands
Follow LBRX for push alerts, or ask the research agent what this filing means.